
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is an immuno-pharma company with a positive outlook due to potential catalysts from ongoing clinical trials, a focus on developing treatments for pancreatic cancer with promising results, and partnerships with major cancer research centers. Risks include balance sheet and liquidity issues, regulatory approvals, and competition. Despite these risks, the company has a strong balance sheet with enough cash to fund operations into late-2026 and a current valuation that presents an attractive opportunity for investors.
Bears say
AIM ImmunoTech is a biotech company with a strong focus on developing new drug therapies for viral and immune-related diseases. However, the company's limited pipeline and current lack of profitability, coupled with the uncertain timing of key clinical data release, make it a risky investment option. Further, the company's changing focus to pancreatic cancer may take some time to materialize into significant financial returns, possibly impacting stock performance in the near future.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares